- Home
- CLLS
CLLS
Cellectis S.A.
as 12-18-2024 1:33pm EST
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
| Founded: | 1999 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 240.2M | IPO Year: | 2007 |
| Target Price: | $7.00 | AVG Volume (30 days): | 63.0K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.69 - $3.77 | Next Earning Date: | 11-04-2024 |
| Revenue: | $36,042,000 | Revenue Growth: | 46.96% |
| Revenue Growth (this year): | 271.02% | Revenue Growth (next year): | 33.48% |
Latest Cellectis S.A. News
CLLS Breaking Stock News: Dive into CLLS Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
GlobeNewswire
14 days ago
Monthly information on share capital and company voting rights
GlobeNewswire
a month ago
Monthly information on share capital and company voting rights
GlobeNewswire
a month ago
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
GlobeNewswire
a month ago
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
GuruFocus.com
a month ago
What To Expect From Cellectis SA (CLLS) Q3 2024 Earnings
GlobeNewswire
2 months ago
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
TipRanks
2 months ago
Cellectis Presents New Gene-Editing Breakthroughs
Compare CLLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLLS Cellectis S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.